As a trusted partner, Bracco demonstrated an integrated approach to imaging that supports evolving clinical needs across MRI, CEUS, CT and AI. The focus was on practical innovation - solutions that help clinicians improve diagnostic confidence, streamline workflows and enhance patient care.

A central highlight was Bracco's MRI portfolio, with particular attention on gadopiclenol and its application across CNS, breast and pediatric imaging. Gadopiclenol is a high relaxivity macrocyclic gadolinium-based contrast agent designed to deliver effective contrast enhancement at a lower approved dose (0.05 mmol/kg), supporting reduced cumulative gadolinium exposure without compromising image quality.

Its high relaxivity enables strong diagnostic performance, aligning with clinical guidance to use the lowest effective dose, particularly in patients requiring repeated imaging.

One key session provided practical guidance on the appropriate use of iodinated contrast agents, particularly in special populations such as elderly, pediatric, pregnant or breastfeeding patients. Through case-based discussions aligned with clinical guidelines, the session addressed common misconceptions, from metformin management to contrast use in pregnancy and same-day imaging, reinforcing individualized, evidence-based decision-making in everyday practice.

Expert-led presentations reinforced key principles shaping modern contrast-enhanced MRI: prioritizing highly stable macrocyclic agents and leveraging higher relaxivity to minimize exposure while maintaining diagnostic performance.

In breast imaging, discussions highlighted gadopiclenol's strategic value as a promising approach to reducing cumulative gadolinium burden in women undergoing repeated MRI screening. High-relaxivity contrast agents agents at lower dose may help address long-term exposure considerations while preserving diagnostic confidence.

In pediatric neuroradiology, where safety considerations are paramount, real-world data highlighted the favorable safety profile and consistent performance of VUEWAY across millions of administrations. Evidence extending beyond clinical trials supports its reliability and reproducibility in daily practice. High relaxivity enables high-quality imaging at lower dose, helping balance diagnostic benefit with patient safety.

Bracco also showcased how AI is becoming part of routine clinical practice. Through AiMIFY^TM, developed with Subtle Medical, the company demonstrated how AI can enhance lesion visualization in brain MRI by increasing contrast between lesions and surrounding tissue, improving contrast-to-noise and lesion-to-background ratios, and reducing artifacts.

The combination of contrast media and AI points to a more integrated future, where digital solutions support radiologists in detecting and characterizing disease with greater clarity and confidence. Early findings from clinical experience indicate that AI has the potential to increase diagnostic yield while supporting more efficient use of contrast media, including the possibility of further reducing gadolinium dose.

More broadly, AI is expected to play an increasing role across MR, CT, mammography and X-ray, helping radiologists achieve clearer visualization with less contrast exposure for patients and the environment.

Beyond MRI, Bracco emphasized the importance of combining imaging modalities to support clinical decision-making. A dedicated symposium explored how CEUS, CT and MRI can work together in the assessment of incidental liver lesions.

Experts highlighted the role of CEUS as a valuable diagnostic tool, capable of characterizing lesions and guiding next steps, sometimes avoiding the need for additional imaging. CT and MRI contributions further demonstrated how modality selection, timing and technique can be optimized to improve diagnostic accuracy and patient management.

Education was a cornerstone of Bracco's presence at ECR 2026. In collaboration with the ESR, Bracco hosted a comprehensive educational program, including three scientific symposia, an educational event and an open forum designed to foster dialogue and knowledge exchange.

These initiatives reflect a long-standing commitment to education and mentorship, with a strong focus on supporting the next generation of radiologists. The partnership with ESOR continues to play a key role in this effort, creating opportunities for young professionals to engage in international training and research.

This commitment is reflected in tangible outcomes. In 2025 alone, Bracco reached 150,000 healthcare professionals through training and workshops, delivered more than 400 accredited programs, engaged over 1,600 experts in medical education, conducted 10,000+ clinical visits and sponsored 126 fellowships worldwide. The Bracco Global Academy further supports continuous learning, with a growing international community and expanding educational content.

Several sessions at ECR brought this educational mission to life. The ESOR AIM China programme highlighted the value of global collaboration in developing emerging talent through research-driven exchanges. A hands-on AI challenge, developed with EuSoMII, demonstrated how new digital tools can be applied to real-world imaging workflows. Meanwhile, the Young Clubs session created a platform for early-career radiologists to connect across subspecialties and contribute to the future of the field.

Bracco's presence at ECR 2026 underscored two connected priorities: advancing diagnostic imaging through meaningful innovation and strengthening the future of radiology through education. By bringing together imaging modalities, AI and a sustained investment in learning, Bracco continues to support radiologists in delivering high-quality care today while helping shape what comes next.